

Expression of the ABCG2 transporter in canine tumor cells

Carlyn Zylstra

ABCG₂ (ATP-Binding Cassette sub-family G, member 2) is a membrane-spanning protein that transports xenobiotics unidirectionally out of cells, preventing the intracellular accumulation of pharmaceutical agents. ABCG₂ was initially identified in a highly chemotherapy-resistant breast cancer cell line, and was demonstrated to be responsible for the resistant phenotype. Since its initial discovery, ABCG₂ expression has been detected in human cancer patients with resistant lymphomas, sarcomas, and carcinomas. Due to the chemotherapy-resistance it imparts, ABCG₂ expression is a poor prognostic indicator in a variety of human tumor types including squamous cell carcinomas, leukemias, lung tumors, and others. Whether or not ABCG₂ contributes to chemotherapeutic resistance in canine tumors is unknown. Thus, we investigated the hypothesis that ABCG₂ is expressed by canine tumor cells.

A variety of archived tumor samples from the Washington State University Oncology Service were evaluated for expression of ABCG₂. In total, 4 osteosarcomas, 4 melanomas, 4 sarcomas, 4 carcinomas, and 1 mast cell tumor were examined using RT PCR and each contained functional ABCG₂ genotype. Immunoblotting to detect ABCG₂ protein was performed on proteins from 2 melanomas, 2 carcinomas, 2 sarcomas, 1 osteosarcoma, and 1 mast cell tumor. ABCG₂ expression was confirmed in all cases, except 1 carcinoma and 1 sarcoma.